MedPath

Olcegepant

Generic Name
Olcegepant
Drug Type
Small Molecule
Chemical Formula
C38H47Br2N9O5
CAS Number
204697-65-4
Unique Ingredient Identifier
WOA5J8TX6M

Overview

Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks. Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine.

Background

Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks. Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine.

Indication

For the treatment of migraine headaches.

Associated Conditions

No associated conditions information available.

FDA Approved Products

Product Name
Manufacturer
Route
Strength
Approved
NDC Code

No FDA products found

No FDA products found for this drug

EMA Approved Products

Medicine Name
EMA Number
Auth. Holder
Country
Drug Type
Status
Issued
Opinion
Revision

No EMA products found

No EMA products found for this drug

Singapore Approved Products

Product Name
Manufacturer
Dosage Form
Strength
Approved
Approval No.
Online

No Singapore products found

No Singapore products found for this drug

China Approved Products

Product Name
Approval No.
Manufacturer
Dosage Form
Trade Name
Strength
Type
Status
Date
Import

No China products found

No China products found for this drug

Australia Approved Products

Product Name
ARTG ID
Sponsor
Status
Reg. Date
Ingredient

No Australia products found

No Australia products found for this drug

© Copyright 2025. All Rights Reserved by MedPath